JP6096401B2 - 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 - Google Patents
筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 Download PDFInfo
- Publication number
- JP6096401B2 JP6096401B2 JP2010270608A JP2010270608A JP6096401B2 JP 6096401 B2 JP6096401 B2 JP 6096401B2 JP 2010270608 A JP2010270608 A JP 2010270608A JP 2010270608 A JP2010270608 A JP 2010270608A JP 6096401 B2 JP6096401 B2 JP 6096401B2
- Authority
- JP
- Japan
- Prior art keywords
- exercise
- ribose
- muscle spasm
- induced muscle
- inhibitor according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Finger-Pressure Massage (AREA)
Description
筋収縮の際、酸素要求量が酸素有効量を超えることがあり、即ち、筋肉が低酸素症となることがある。運動中の低酸素筋肉中では、エネルギー製造はアデノシン三リン酸(ATP)の好気性から嫌気性生産へと移り変わる。グルコースからの嫌気性エネルギー製造、即ち解糖は最終産物として乳酸を提供する。同時に、ATPは分解してイノシン及びヒポキサンチンとなり、その更なる代謝は細胞障害を及ぼしうる非常に反応性な分子であるフリーラジカルの生成につながる。乳酸の存在、フリーラジカルにより引き起こされる障害、又は何らかのその他のメカニズムが筋肉の痙攣及び痛みの主因であるかどうかはわかっていない。
経験豊かな男性マラソンランナー、年齢43才は15回マラソンを完了している。彼のトレーニングメニューは週当り4〜5回、8〜10マイル走ることから成る。トレーニング走行の際、並びに特にマラソンレースの際及び後に、彼は様々な度合いの筋肉痙攣及び筋肉痛を体感している。彼は走った後に疲労を感じている。
週に1又は2回2マイルのジョギングをする41才の女性は、運動の5〜10時間後に始まり、そして2〜3日間持続する運動誘導筋肉痛を経験している。この痛みは彼女が快適に仕事ができないほどにひどいものであった。
気腫を患う老女患者は彼女の手足において筋肉痙攣及び痛みを感じていた。これらの徴候は軽い運動によってさえも増強された。彼女は毎朝D−リボースを2〜4gの用量で摂取し始めた。彼女は用量をその日の彼女の予測の活動レベルに従って調節し、より活動の多い日にはより多い用量を摂取した。彼女は痙攣の即効且つ完全な緩和を体感した。この緩和は4ヶ月間のリボース摂取の間維持された。
週末トーナメントにてテニスをする68才の男性を各ゲームの翌日に疲労及び筋肉痛を感じていた。彼は痛み、剛直及び疲労のために2日連続でテニスするのは困難と考え、それが原因で2日目のゲームでは集中力を欠いてしまっていた。このような徴候の結果、彼はラウンド−ロビントーナメントを所望通りに終了することができなかった。週末トーナメントが非常に暑く、多湿な気候で行われる間、彼は1日目のゲームの後にオレンジジュース中の3gのD−リボースを摂取した。翌日、通常の痛み及び疲労を感じるのではなく、彼はピークレベルでテニスをすることができた。
Claims (14)
- 健常人に投与するための運動誘導筋肉痙攣発症阻止剤であって、当該健常人に運動を開始する前に投与するための乾燥粉末形態のリボースを含んでなり、当該阻止剤の投与が活力を向上させることを特徴とし、前記阻止剤がサッシェの中に入っており、そのサッシェは開封することでその内容物を食品又は飲料品に添加できるようになっている、食品又は飲料品を除く、運動誘導筋肉痙攣発症阻止剤。
- リボースが運動の際に骨格筋へと運ばれるよう運動を開始する前に投与することを特徴とする、請求項1記載の運動誘導筋肉痙攣発症阻止剤。
- リボースの量が1〜60gである、請求項1又は2記載の運動誘導筋肉痙攣発症阻止剤。
- リボースの量が2〜10gである、請求項3記載の運動誘導筋肉痙攣発症阻止剤。
- リボースを運動開始の少なくとも10分前、しかしながら4時間前以内に投与する、請求項1〜4のいずれか1項に記載の運動誘導筋肉痙攣発症阻止剤。
- 前記組成物が単位投与形態をとっている、請求項1〜5のいずれか1項に記載の運動誘導筋肉痙攣発症阻止剤。
- 飲食物であることを除く、請求項1〜6のいずれか1項に記載の運動誘導筋肉痙攣発症阻止剤。
- 健常哺乳動物に運動を開始する前に投与するためのリボースからなり、サッシェの中に入っており、そのサッシェは開封することでその内容物を食品又は飲料品に添加できるようになっている、食品又は飲料品を除く、運動誘導筋肉痙攣発症阻止剤。
- リボースが運動の際に骨格筋へと運ばれるよう運動を開始する前に投与することを特徴とする、請求項8記載の運動誘導筋肉痙攣発症阻止剤。
- リボースの量が1〜60gである、請求項8又は9記載の運動誘導筋肉痙攣発症阻止剤。
- リボースの量が2〜10gである、請求項10記載の運動誘導筋肉痙攣発症阻止剤。
- リボースを運動開始の少なくとも10分前、しかしながら4時間前以内に投与する、請求項8〜11のいずれか1項に記載の運動誘導筋肉痙攣発症阻止剤。
- 前記組成物が単位投与形態をとっている、請求項8〜12のいずれか1項に記載の運動誘導筋肉痙攣発症阻止剤。
- 飲食物であることを除く、請求項8〜13のいずれか1項に記載の運動誘導筋肉痙攣発症阻止剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/405,464 US6159943A (en) | 1999-09-24 | 1999-09-24 | Use of ribose to prevent cramping and soreness in muscles |
US09/405,464 | 1999-09-24 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001524411A Division JP4945710B2 (ja) | 1999-09-24 | 2000-09-22 | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014247292A Division JP2015052018A (ja) | 1999-09-24 | 2014-12-05 | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011093910A JP2011093910A (ja) | 2011-05-12 |
JP6096401B2 true JP6096401B2 (ja) | 2017-03-15 |
Family
ID=23603807
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001524411A Expired - Lifetime JP4945710B2 (ja) | 1999-09-24 | 2000-09-22 | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 |
JP2010270608A Expired - Lifetime JP6096401B2 (ja) | 1999-09-24 | 2010-12-03 | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 |
JP2014247292A Pending JP2015052018A (ja) | 1999-09-24 | 2014-12-05 | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001524411A Expired - Lifetime JP4945710B2 (ja) | 1999-09-24 | 2000-09-22 | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014247292A Pending JP2015052018A (ja) | 1999-09-24 | 2014-12-05 | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US6159943A (ja) |
EP (1) | EP1235581B1 (ja) |
JP (3) | JP4945710B2 (ja) |
CN (1) | CN1247201C (ja) |
AT (1) | ATE322273T1 (ja) |
AU (1) | AU783796B2 (ja) |
BR (1) | BR0014235A (ja) |
CA (1) | CA2383284C (ja) |
DE (1) | DE60027197T2 (ja) |
ES (1) | ES2257319T3 (ja) |
GB (1) | GB2352175B (ja) |
MX (1) | MXPA02003150A (ja) |
WO (1) | WO2001020969A2 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119933A1 (en) * | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
US6511964B2 (en) | 1999-09-24 | 2003-01-28 | Bioenergy, Inc. | Method for treating acute mountain sickness |
US6159943A (en) * | 1999-09-24 | 2000-12-12 | Bioenergy, Inc. | Use of ribose to prevent cramping and soreness in muscles |
US6703370B1 (en) * | 1999-10-27 | 2004-03-09 | Bioenergy, Inc. | Use of ribose to treat fibromyalgia |
EP1095658A3 (en) * | 1999-10-27 | 2002-10-23 | Bioenergy Inc. | Use of ribose to treat fibromyalgia |
CA2397707A1 (en) * | 2000-01-07 | 2001-07-19 | Susan S. Percival | Compositions for enhancing the immune response |
WO2001052831A1 (en) | 2000-01-20 | 2001-07-26 | Bioenergy Inc. | Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans |
FR2822642B1 (fr) * | 2001-03-30 | 2005-03-04 | Roquette Freres | Denree alimentaire a liberation d'energie prolongee |
EP1247525A1 (en) * | 2001-04-02 | 2002-10-09 | Bioenergy Inc. | Use of a monosaccharide in the manufacture of a medicament against acute mountain sickness |
US7629329B2 (en) * | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
US20030212006A1 (en) * | 2002-05-13 | 2003-11-13 | Seifert John G. | Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals |
US20050048136A1 (en) * | 2003-08-27 | 2005-03-03 | Choudhry Muhammad S. | Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness |
EP1703913B1 (en) * | 2004-01-14 | 2012-08-01 | RiboCor, Inc. | Use of ribose in recovery from anaesthesia |
US20100099630A1 (en) * | 2004-04-29 | 2010-04-22 | Maccarter Dean J | Method for improving ventilatory efficiency |
EP1786436B1 (en) * | 2004-04-29 | 2012-11-14 | RiboCor, Inc. | Method for improving ventilatory efficiency |
US7968138B2 (en) * | 2004-07-23 | 2011-06-28 | Arnold Nerenberg | Food sweetener |
US20060135440A1 (en) * | 2004-12-14 | 2006-06-22 | Houston Mark C | Use of ribose to alleviate rhabdomyolysis and the side effects of statin drugs |
US20070172542A1 (en) * | 2005-07-18 | 2007-07-26 | Next Proteins, Inc. | Stimulant-containing nutrition bar product and method of manufacture |
US7566463B2 (en) * | 2006-05-03 | 2009-07-28 | C. B. Fleet Company | Oral rehydration compositions |
ES2352154T3 (es) * | 2007-01-23 | 2011-02-16 | Bioenergy Inc. | Uso de d-ribosa para tratar arritmias cardiacas. |
US20090061016A1 (en) * | 2007-09-05 | 2009-03-05 | Selzer Jonathan A | Seawater Based Dietary Supplement Product for Energy and Electrolyte Replacement |
US20100055206A1 (en) * | 2008-04-02 | 2010-03-04 | St Cyr John A | Use of ribose in first response to acute myocardial infarction |
CA2734769A1 (en) * | 2008-08-20 | 2010-02-25 | Bioenergy, Inc. | Use of d-ribose for fatigued subjects |
US20120045426A1 (en) * | 2010-08-21 | 2012-02-23 | St Cyr John A | Compositions for reducing the deleterious effects of stress and aging |
US10821123B2 (en) | 2016-02-01 | 2020-11-03 | Bioenergy Life Science, Inc. | Use of ribose for treatment of subjects having congestive heart failure |
WO2019200132A1 (en) * | 2018-04-12 | 2019-10-17 | Metabolic Recovery Systems, LLC | Compositions and methods for supplementing the diet |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH570122A5 (ja) * | 1970-12-23 | 1975-12-15 | Givaudan & Cie Sa | |
JPS5921376A (ja) * | 1982-07-26 | 1984-02-03 | Akiji Kotani | 魚肉ねり製品発色剤、および魚肉ねり製品の発色方法 |
US4605644A (en) * | 1985-02-07 | 1986-08-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia employing ribose and adenine |
US4719201A (en) * | 1985-02-07 | 1988-01-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia |
US4824660A (en) * | 1985-06-06 | 1989-04-25 | Paul S. Angello | Method of determining the viability of tissue in an organism |
JPS6232860A (ja) * | 1985-08-06 | 1987-02-12 | Riichiro Yamazaki | 健康食品 |
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US4828845A (en) * | 1986-12-16 | 1989-05-09 | Warner-Lambert Company | Xylitol coated comestible and method of preparation |
US4871718A (en) * | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
US4968719A (en) * | 1989-04-03 | 1990-11-06 | Sigma Tau, Industrie Farmaceutiche Riunite Spa | Method for treating vascular disease |
US5114723A (en) * | 1990-02-27 | 1992-05-19 | University Of Texas System Board Of Regents | Beverage compositions for human consumption |
CA2048003A1 (en) * | 1990-08-21 | 1992-02-22 | Serge Burner | Tricyclic pyridone derivatives |
GB9101244D0 (en) * | 1991-01-19 | 1991-02-27 | Wellcome Found | Amide derivatives and their therapeutic use |
IT1247125B (it) * | 1991-03-01 | 1994-12-12 | Depha Team Srl | Composizioni dietetiche o farmaceutiche per il ripristino del contenuto cellulare degli adenin nucleotidi nel muscolo scheletrico e cardiaco. |
US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
DE4228215A1 (de) * | 1992-08-25 | 1994-03-03 | Pliml Wolfgang | Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen |
US5536751A (en) * | 1994-05-09 | 1996-07-16 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof |
EP0729758A3 (en) * | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
US5707971A (en) * | 1995-06-07 | 1998-01-13 | Life Resuscitation Technologies, Inc. | Modulation of glycolytic ATP production |
GB9715340D0 (en) * | 1997-07-22 | 1997-09-24 | Cerestar Holding Bv | Beverages for enhanced physical performance |
JP4295840B2 (ja) * | 1997-12-09 | 2009-07-15 | 株式会社林原生物化学研究所 | 血行改善剤 |
US6159942A (en) * | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
US6159943A (en) * | 1999-09-24 | 2000-12-12 | Bioenergy, Inc. | Use of ribose to prevent cramping and soreness in muscles |
-
1999
- 1999-09-24 US US09/405,464 patent/US6159943A/en not_active Expired - Lifetime
-
2000
- 2000-09-21 GB GB0023103A patent/GB2352175B/en not_active Expired - Lifetime
- 2000-09-22 AU AU38842/01A patent/AU783796B2/en not_active Expired
- 2000-09-22 ES ES00963748T patent/ES2257319T3/es not_active Expired - Lifetime
- 2000-09-22 WO PCT/US2000/026140 patent/WO2001020969A2/en active IP Right Grant
- 2000-09-22 CN CNB008142769A patent/CN1247201C/zh not_active Expired - Lifetime
- 2000-09-22 MX MXPA02003150A patent/MXPA02003150A/es unknown
- 2000-09-22 DE DE60027197T patent/DE60027197T2/de not_active Expired - Lifetime
- 2000-09-22 CA CA2383284A patent/CA2383284C/en not_active Expired - Lifetime
- 2000-09-22 BR BR0014235-2A patent/BR0014235A/pt not_active Application Discontinuation
- 2000-09-22 EP EP00963748A patent/EP1235581B1/en not_active Expired - Lifetime
- 2000-09-22 AT AT00963748T patent/ATE322273T1/de not_active IP Right Cessation
- 2000-09-22 JP JP2001524411A patent/JP4945710B2/ja not_active Expired - Lifetime
-
2010
- 2010-12-03 JP JP2010270608A patent/JP6096401B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-05 JP JP2014247292A patent/JP2015052018A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
GB2352175A (en) | 2001-01-24 |
DE60027197T2 (de) | 2006-08-24 |
US6159943A (en) | 2000-12-12 |
MXPA02003150A (es) | 2003-08-20 |
BR0014235A (pt) | 2002-12-31 |
CA2383284A1 (en) | 2001-03-29 |
DE60027197D1 (de) | 2006-05-18 |
CN1247201C (zh) | 2006-03-29 |
GB2352175B (en) | 2001-07-18 |
EP1235581B1 (en) | 2006-04-05 |
JP2015052018A (ja) | 2015-03-19 |
CA2383284C (en) | 2011-03-15 |
GB0023103D0 (en) | 2000-11-01 |
WO2001020969A3 (en) | 2002-07-11 |
WO2001020969A2 (en) | 2001-03-29 |
AU783796B2 (en) | 2005-12-08 |
JP4945710B2 (ja) | 2012-06-06 |
AU3884201A (en) | 2001-04-24 |
ATE322273T1 (de) | 2006-04-15 |
EP1235581A2 (en) | 2002-09-04 |
JP2011093910A (ja) | 2011-05-12 |
ES2257319T3 (es) | 2006-08-01 |
CN1450904A (zh) | 2003-10-22 |
JP2003516315A (ja) | 2003-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6096401B2 (ja) | 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用 | |
EP1087779B1 (en) | Compositions for increasing energy in vivo | |
US6534480B2 (en) | Compositions for increasing energy in vivo | |
Kreider | Creatine supplementation: analysis of ergogenic value, medical safety, and concerns | |
US7740878B2 (en) | Use of betaine to enhance exercise performance | |
US6429198B1 (en) | Compositions for increasing athletic performance in mammals | |
KR100613618B1 (ko) | 운동에 동반하여 일어나는 산화적 대사를 지속시키는 방법 및스포츠용 음식물 | |
Clapp et al. | A review of fluid replacement for workers in hot jobs | |
US20050048136A1 (en) | Rehydrating beverage with Rhodiola crenulata and D-ribose that enhances blood oxygen and relieves post-exertional muscle cramping and soreness | |
Singh | Fluid balance and exercise performance | |
US20080108698A1 (en) | Nutrient Supplement and Use of the Same | |
EP1745789A1 (en) | Compositions comprising ribose for increasing energy in vivo | |
Campos-Perez et al. | Influence of substances present in energy and sports drinks in improving athletic performance | |
McNaughton et al. | Buffering agents: Sodium bicarbonate, sodium citrate and sodium phosphate | |
Maughan | Sports nutrition: an overview | |
Volek | Creatine supplementation and the strength athlete | |
Kreider et al. | Creatine: The ergogenic/anabolic supplement | |
McNaughton et al. | Buffering agents | |
Burns et al. | Sports beverages | |
Ziegenfussa et al. | 12 Nutritional Supplements to Enhance Recovery | |
Crossfield | Rhodiola and ginkgo combination boosts endurance (no training required) Supplementation with extracts of Ginkgo biloba and Rhodiola crenulata increases the stamina of young men. This is shown in a human study published in 2009 in the Chinese Journal of Integrative Medicine. Study The researchers, at the University of Hong Kong, divided 67 young men into 2 groups. For 7 weeks, they gave the men in one group placebo capsules and the men in the other group capsules containing extracts of Ginkgo biloba and Rhodiola crenulata in a ratio of 1: 9. The men took 4 capsules each day, each containing 270 milligrams of extract mixture. They took 2 capsules with breakfast and 2 capsules with dinner. | |
Mounteer | The use of ergogenic aids in athletes | |
Pitkin | The effect of magnesium supplementation on high and low dietary magnesium intake on resting, during and recovering from exercise on blood pressure, performance and serum levels of magnesium (Mg2+). | |
Mckune | Creatine supplementation and enhanced sport and exercise performance s forum | |
JP2001190246A (ja) | 果糖を主原料とする打錠成形してなる加工食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120306 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130528 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130827 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131128 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141205 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150120 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150403 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6096401 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |